利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.054 秒)

    NOVEL COMPOUNDS
    12.
    发明申请
    NOVEL COMPOUNDS 审中-公开
    新型化合物

    公开(公告)号：US20120202811A1

    公开(公告)日：2012-08-09

    申请号：US13451196

    申请日：2012-04-19

    申请人： Alan David Borthwick ,  Deirdre Mary Bernadette Hickey ,  John Liddle ,  Andrew McMurtrie Mason

    发明人： Alan David Borthwick ,  Deirdre Mary Bernadette Hickey ,  John Liddle ,  Andrew McMurtrie Mason

    IPC分类号： A61K31/5377 ,  A61P13/08

    CPC分类号： A61K31/5377 ,  C07D401/06 ,  C07D413/14

    摘要： Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.

    摘要翻译： 式（I）的化合物，其中R 1是2-茚满基，R 2是1-甲基丙基，R 3是选自2,6-二甲基-3-吡啶基或4,6-二甲基-3-吡啶基的基团，R 4表示甲基和R 5 表示氢或甲基，或者R4和R5与它们所连接的氮原子一起代表吗啉代及其药学上可接受的衍生物，其制备方法，含有它们的药物组合物及其在药物中的用途，特别是其用作 催产素拮抗剂。

    Compounds
    13.
    发明授权
    Compounds 有权
    化合物

    公开(公告)号：US07919492B2

    公开(公告)日：2011-04-05

    申请号：US12850386

    申请日：2010-08-04

    申请人： Alan David Borthwick ,  Deirdre Mary Bernadette Hickey ,  John Liddle ,  Andrew McMurtrie Mason

    发明人： Alan David Borthwick ,  Deirdre Mary Bernadette Hickey ,  John Liddle ,  Andrew McMurtrie Mason

    IPC分类号： A61K31/5377

    CPC分类号： A61K31/5377 ,  C07D401/06 ,  C07D413/14

    摘要： Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.

    摘要翻译： 式（I）的化合物，其中R 1是2-茚满基，R 2是1-甲基丙基，R 3是选自2,6-二甲基-3-吡啶基或4,6-二甲基-3-吡啶基的基团，R 4表示甲基和R 5 表示氢或甲基，或者R4和R5与它们所连接的氮原子一起代表吗啉代及其药学上可接受的衍生物，其制备方法，含有它们的药物组合物及其在药物中的用途，特别是其用作 催产素拮抗剂。

    NOVEL COMPOUNDS
    14.
    发明申请
    NOVEL COMPOUNDS 有权
    新型化合物

    公开(公告)号：US20110152262A1

    公开(公告)日：2011-06-23

    申请号：US13035366

    申请日：2011-02-25

    申请人： Alan David Borthwick ,  Deirdre Mary Bernadette Hickey ,  John Liddle ,  Andrew McMurtrie Mason

    发明人： Alan David Borthwick ,  Deirdre Mary Bernadette Hickey ,  John Liddle ,  Andrew McMurtrie Mason

    IPC分类号： A61K31/5355 ,  C07D413/14 ,  A61P15/12 ,  A61P15/06

    CPC分类号： A61K31/5377 ,  C07D401/06 ,  C07D413/14

    摘要： Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.

    摘要翻译： 式（I）的化合物，其中R 1是2-茚满基，R 2是1-甲基丙基，R 3是选自2,6-二甲基-3-吡啶基或4,6-二甲基-3-吡啶基的基团，R 4表示甲基和R 5 表示氢或甲基，或者R4和R5与它们所连接的氮原子一起代表吗啉代及其药学上可接受的衍生物，其制备方法，含有它们的药物组合物及其在药物中的用途，特别是其用作 催产素拮抗剂。

    Pyrazolopyridines and pyrazolopyridazines as antidiabetics
    16.
    发明授权
    Pyrazolopyridines and pyrazolopyridazines as antidiabetics 失效
    吡唑并吡啶类和吡唑并吡啶类作为抗糖尿病药

    公开(公告)号：US07297792B2

    公开(公告)日：2007-11-20

    申请号：US11422338

    申请日：2006-06-06

    申请人： Stephen Garland ,  David Haigh ,  Deidre Mary Bernadette Hickey ,  John Liddle ,  David Glynn Smith ,  Robert William Ward ,  Jason Witherington

    发明人： Stephen Garland ,  David Haigh ,  Deidre Mary Bernadette Hickey ,  John Liddle ,  David Glynn Smith ,  Robert William Ward ,  Jason Witherington

    IPC分类号： C07D413/00

    CPC分类号： C07D471/04 ,  C07D213/85 ,  C07D487/04

    摘要： The present invention includes compound of formula (I), or a derivative thereof, wherein Y is CH or N; R1 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl, aralkyl wherein the aryl and the alkyl moieties may each independently be unsubstituted or substituted, aralkenyl wherein the aryl, and alkenyl moieties may each independently be unsubstituted or substituted, unsubstituted or substituted heterocyclyl, or heterocyclylalkyl wherein the heterocyclcyl and the alkyl moieties may each inedepently be unsubstituted or substituted; and R2 is unsubstituted aryl or unsubstituted or substituted or substituted heteroaryl. Additionally the present invention inlcudes a process for preparing such a compound, a pharmaceutical composition containing such a compound, and the use of such a compound in medicine.

    摘要翻译： 本发明包括式（I）化合物或其衍生物，其中Y为CH或N; R 1是未取代或取代的烷基，未取代或取代的环烷基，未取代或取代的烯基，未取代或取代的环烯基，未取代或取代的芳基，芳烷基，其中芳基和烷基部分各自独立地为未取代或取代的 芳基和烯基部分可以各自独立地是未取代的或取代的，未取代的或取代的杂环基或杂环基烷基，其中杂环基和烷基部分各自是未取代的或取代的; R 2是未取代的芳基或未取代或取代或取代的杂芳基。 另外本发明涉及制备这种化合物的方法，含有这种化合物的药物组合物，以及这种化合物在医药中的用途。

    Compounds
    18.
    发明授权
    Compounds 有权
    化合物

    公开(公告)号：US08202864B2

    公开(公告)日：2012-06-19

    申请号：US13035366

    申请日：2011-02-25

    申请人： Alan David Borthwick ,  Deirdre Mary Bernadette Hickey ,  John Liddle ,  Andrew McMurtrie Mason

    发明人： Alan David Borthwick ,  Deirdre Mary Bernadette Hickey ,  John Liddle ,  Andrew McMurtrie Mason

    IPC分类号： A61K31/5377 ,  C07D413/14

    CPC分类号： A61K31/5377 ,  C07D401/06 ,  C07D413/14

    摘要： Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.

    摘要翻译： 式（I）的化合物，其中R 1是2-茚满基，R 2是1-甲基丙基，R 3是选自2,6-二甲基-3-吡啶基或4,6-二甲基-3-吡啶基的基团，R 4表示甲基和R 5 描述了氢或甲基，或者R4和R5与它们所连接的氮原子一起代表吗啉代及其药学上可接受的衍生物，以及其制备方法，含有它们的药物组合物及其在药物中的用途，特别是其作为催产素的用途 拮抗剂

    Substituted diketopiperazines and their use as oxytocin antagonists
    19.
    发明授权
    Substituted diketopiperazines and their use as oxytocin antagonists 有权
    取代的二酮哌嗪及其作为催产素拮抗剂的用途

    公开(公告)号：US08071594B2

    公开(公告)日：2011-12-06

    申请号：US10561498

    申请日：2004-06-22

    申请人： John Liddle

    发明人： John Liddle

    IPC分类号： A61K31/496 ,  C07D241/08 ,  C07D413/02

    CPC分类号： A61K31/5377 ,  A61K9/0053 ,  C07D241/08 ,  C07D413/06 ,  C07D413/14

    摘要： Compounds of formula (1) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is 2-methyl-1,3-oxazol-4-yl and R4 and R5 together with the notrogen atom to which they are attached represents morpholino, process for their preparation, pharmaceutical compositions containing them and their use in medicine.

    摘要翻译： 式（1）的化合物，其中R 1是2-茚满基，R 2是1-甲基丙基，R 3是2-甲基-1,3-恶唑-4-基，R 4和R 5与它们所连接的雄激素原子一起代表吗啉代 ，其制备方法，含有它们的药物组合物及其在医药中的用途。

    NOVEL COMPOUNDS
    20.
    发明申请
    NOVEL COMPOUNDS 有权
    新型化合物

    公开(公告)号：US20100305127A1

    公开(公告)日：2010-12-02

    申请号：US12850386

    申请日：2010-08-04

    申请人： Alan David Borthwick ,  Deirdre Mary Bernadette Hickey ,  John Liddle ,  Andrew McMurtrie Mason

    发明人： Alan David Borthwick ,  Deirdre Mary Bernadette Hickey ,  John Liddle ,  Andrew McMurtrie Mason

    IPC分类号： A61K31/5377 ,  A61P15/06 ,  A61P15/12

    CPC分类号： A61K31/5377 ,  C07D401/06 ,  C07D413/14

    摘要： Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.

    摘要翻译： 式（I）的化合物，其中R 1是2-茚满基，R 2是1-甲基丙基，R 3是选自2,6-二甲基-3-吡啶基或4,6-二甲基-3-吡啶基的基团，R 4表示甲基和R 5 表示氢或甲基，或者R4和R5与它们所连接的氮原子一起代表吗啉代及其药学上可接受的衍生物，其制备方法，含有它们的药物组合物及其在药物中的用途，特别是其用作 催产素拮抗剂。